UBS Group set a €52.50 ($61.05) target price on Brenntag (FRA:BNR) in a research note published on Wednesday, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.
Several other research analysts have also recently weighed in on BNR. Jefferies Financial Group decreased their price objective on shares of Seres Therapeutics from $6.00 to $4.00 and set a hold rating for the company in a report on Monday, July 1st. Berenberg Bank reissued a buy rating and set a GBX 250 ($3.27) price objective on shares of in a report on Tuesday, June 18th. Goldman Sachs Group initiated coverage on shares of Beyond Meat in a report on Monday, May 27th. They set a neutral rating and a $67.00 price objective for the company. Kepler Capital Markets set a €112.00 ($130.23) price objective on shares of LEG Immobilien and gave the company a buy rating in a report on Thursday, May 9th. Finally, Deutsche Bank reissued a hold rating and set a GBX 1,775 ($23.19) price objective on shares of in a report on Wednesday, June 26th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Brenntag has a consensus rating of Buy and a consensus price target of €52.77 ($61.36).
BNR opened at €43.60 ($50.70) on Wednesday. The firm’s 50 day moving average is €43.04. Brenntag has a twelve month low of €43.06 ($50.07) and a twelve month high of €56.25 ($65.41).
Brenntag AG, a chemical distribution company, purchases and supplies industrial and specialty chemicals in Europe, the Middle East, Africa, North America, Latin America, the Asia Pacific, and internationally. The company also provides value added services. It serves customers in various end-market industries, such as adhesives, paints, oil and gas, food, water treatment, personal care, and pharmaceuticals.
Read More: How is the LIBOR rate calculated?
Receive News & Ratings for Brenntag Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brenntag and related companies with MarketBeat.com's FREE daily email newsletter.